HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
HIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use KYLEENA safely and effectively. See full prescribing information for KYLEENA. KYLEENA (levonorgestrel-releasing intrauterine system) Initial U.S. Approval: 2000 ----- RECENT MAJOR CHANGES -----
Download HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
Information
Domain:
Source:
Link to this page:
Documents from same domain
NDA 203159 Skyla FDA Approved 1 Mar 2018 1
labeling.bayerhealthcare.comNDA 203159 Skyla FDA Approved 1 Mar 2018 2
FDA-Approved Patient Labeling Patient …
labeling.bayerhealthcare.comNDA 21225 Mirena FDA Approved 08 June 2017 FDA-Approved Patient Labeling Patient Information Mirena® (mur-ā-nah) (levonorgestrel-releasing intrauterine system)
When you’re done having children, condersi Essure
labeling.bayerhealthcare.com6 7 1YOUR YCMPLELRTOGILDRHSLR®VVOULRiUYsLIOUL You should speak to your doctor if: • You are taking or receiving therapy that suppresses your immune system Examples include
HIGHLIGHTS OF PRESCRIBING INFORMATION than …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use YAZ safely and effectively. See full …
HIGHLIGHTS OF PRESCRIBING INFORMATION …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NEXAVAR safely and effectively. See full prescribing information for NEXAVAR.
HIGHLIGHTS OF PRESCRIBING INFORMATION …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use YASMIN safely and effectively. See full prescribing information …
myBETAapp™ Instructions for Use - Bayer HealthCare
labeling.bayerhealthcare.com1 myBETAapp™ Instructions for Use Contents 1 Overview of myBETAapp ..... 1
HIGHLIGHTS OF PRESCRIBING INFORMATION …
labeling.bayerhealthcare.comNDA 21225 Mirena FDA Approved 08 June 2017 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use
HIGHLIGHTS OF PRESCRIBING INFORMATION …
labeling.bayerhealthcare.com2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE KOVALTRY, Antihemophilic Factor (Recombinant), is a recombinant, human …
This Medication Guide has been approved by the …
labeling.bayerhealthcare.comMEDICATION GUIDE GADAVIST (gad-a-vist) (gadobutrol) Injection for intravenous use What is Gadavist? • Gadavist is a prescription medicine called a gadolinium-based contrast agent (GBCA
Related documents
HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use SKYLA safely and effectively. See full prescribing information for SKYLA. SKYLA (levonorgestrel-releasing intrauterine system) Initial U.S. Approval: 2000 •---- …
HIGHLIGHTS OF PRESCRIBING INFORMATION thereafter or …
docs.boehringer-ingelheim.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014 -----RECENT MAJOR CHANGES-----
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
documents.impaxlabs.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RYTARY safely and effectively. See full prescribing information for RYTARY. RYTARY (carbidopa and levodopa) extended-release capsules, for oral use Initial U.S. Approval: 1975 -----INDICATIONS AND USAGE-----
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use MIRENA safely and effectively. See full prescribing information for MIRENA. MIRENA (levonorgestrel-releasing intrauterine system) Initial U.S. Approval: 2000 -----RECENT MAJOR CHANGES-----
HIGHLIGHTS OF PRESCRIBING INFORMATION Before …
docs.boehringer-ingelheim.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JARDIANCE safely and effectively. See full prescribing information for JARDIANCE. • JARDIANCE ® (empagliflozin) tablets, for oral use . Initial U.S. Approval: 2014 . …
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.merck.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) tablets, for oral use Initial U.S. Approval: 2006-----INDICATIONS AND USAGE members -----
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.alnylam.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ONPATTRO® safely and effectively. See full prescribing information for ONPATTRO. ONPATTRO (patisiran) lipid complex injection, for intravenous use Initial U.S. Approval: 2018 -----RECENT MAJOR CHANGES-----
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.pi.amgen.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARANESP-safely and effectively. See full prescribing information for ARANESP. -ARANESP® (darbepoetin alfa) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2001 WARNING: ESAs INCREASE THE RISK OF DEATH,